Novel KRAS Inhibitors Demonstrate Efficacy Against NF1 Nerve Tumors

Preclinical studies have shown a new class of KRAS inhibitors can shrink NF1 nerve tumors. This research offers a promising new therapeutic direction for patients with neurofibromatosis type 1, a genetic disorder causing nerve tumor growth.